Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir
about
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsThe role of drug transporters in the kidney: lessons from tenofovirInsights into Phosphate Cooperativity and Influence of Substrate Modifications on Binding and Catalysis of Hexameric Purine Nucleoside PhosphorylasesSensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosidesMeasurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patientsChanging patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.Tenofovir disoproxil fumarate for the treatment of HIV infection.Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals.Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.Use of antineoplastic agents in patients with cancer who have HIV/AIDS.Drug interactions in the management of HIV infection.Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.Tenofovir-induced kidney injury.Drug interactions in the management of HIV infection: an update.Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-EmtricitabinePharmacogenetics of tenofovir treatment.Renal toxicity associated with tenofovir use.Mechanism of active renal tubular efflux of tenofovir.Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent.Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction.The frequency of adjusted renal dosing of tenofovir DF and its effects on patient outcomes.Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.The 5(th) International Workshop on Clinical Pharmacology of HIV Therapy.Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
P2860
Q24674939-38C6095E-13A6-4572-ADBD-5D7854301C3CQ26866489-225EFBE0-CE62-49E1-A2C5-DB21908EB716Q27672664-D5375A17-9B90-407E-89A0-3868B971F021Q28485227-BB86A9B8-3933-42F2-B050-8580A46D1172Q33770032-6D52022A-0961-4C44-964A-CE625888F1E2Q34414078-68699A50-B1D1-4A65-9C5A-28B8D39AA134Q34569309-CBA92E02-85EA-4F82-9B3B-B4694B3073EEQ34737466-1E27AEB1-4164-41DF-A1EA-135C0629DEDDQ35174468-54F38EAD-D57F-4A70-BDC0-AC80B6A7C899Q35898538-2C49D401-9264-4328-BDDF-8B3AAC90AC9DQ35932561-7D38845A-5456-4503-8171-6F2E3B20AC80Q36066083-220CFE36-F1DC-49DC-B212-7345865E2093Q36188725-4DA7F503-490F-4A47-98AC-F2DED98CAC5AQ36429743-DC0E5D33-8A68-4075-99C8-438E329478B1Q36558253-5C739A6E-39BE-4058-8BFE-5829302DACB7Q36762441-820AF180-D192-4E51-90A4-05C96612EE0DQ37000733-0452046E-6F53-4D07-96DB-66F32D0E176DQ37190767-5C291EDE-FE32-4BF1-9F70-263D1CD8B7A0Q37203781-7691AC09-E5B0-4EA9-ACCE-7D5A156CC60EQ37618231-24DAEDB7-4B1E-4873-B3EF-28F561B07E8FQ37729160-2A0E1C47-F4EB-4266-9070-1E0CDBC72582Q38665179-E49D6850-26BA-45A6-950A-B14FC28F738EQ41915160-A3EF09EA-5E80-4DCF-A4B8-D80F110A209AQ42747686-B5DD4B62-12E9-4618-8FCC-1B834F2DE0A1Q43279654-AB90EC82-165C-45EA-82D1-4041B46641FDQ43646614-CB2AA7F0-B967-4B0D-9880-A701C107D143Q43798415-0B62792A-07AA-4848-947B-12189E9A87D1Q46807623-749CC95A-BF98-43A7-8DD5-3AD4A1A58B7EQ47305594-C193A12A-3F33-45F0-B8CE-10A1C5E9B0D7Q50576419-36D9987E-DCAA-403C-BDF2-E0BBBADC4CA7
P2860
Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Role of purine nucleoside phos ...... nol, ganciclovir, or tenofovir
@ast
Role of purine nucleoside phos ...... nol, ganciclovir, or tenofovir
@en
Role of purine nucleoside phos ...... nol, ganciclovir, or tenofovir
@en-gb
Role of purine nucleoside phos ...... nol, ganciclovir, or tenofovir
@nl
type
label
Role of purine nucleoside phos ...... nol, ganciclovir, or tenofovir
@ast
Role of purine nucleoside phos ...... nol, ganciclovir, or tenofovir
@en
Role of purine nucleoside phos ...... nol, ganciclovir, or tenofovir
@en-gb
Role of purine nucleoside phos ...... nol, ganciclovir, or tenofovir
@nl
prefLabel
Role of purine nucleoside phos ...... nol, ganciclovir, or tenofovir
@ast
Role of purine nucleoside phos ...... nol, ganciclovir, or tenofovir
@en
Role of purine nucleoside phos ...... nol, ganciclovir, or tenofovir
@en-gb
Role of purine nucleoside phos ...... nol, ganciclovir, or tenofovir
@nl
P2860
P1476
Role of purine nucleoside phos ...... nol, ganciclovir, or tenofovir
@en
P2093
Arnold Fridland
Loren Olson
P2860
P304
P356
10.1128/AAC.48.4.1089-1095.2004
P407
P577
2004-04-01T00:00:00Z